Pharma major Lupin’s Aurangabad facility gets Establishment Inspection Report from USFDA

Pharma major Lupin has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Aurangabad facility.

FP Trending April 03, 2020 15:40:35 IST
Pharma major Lupin’s Aurangabad facility gets Establishment Inspection Report from USFDA

Pharma major Lupin has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Aurangabad facility.

The inspection for the facility was carried out by the USFDA between February 10 and February 14 this  year.

Nilesh Gupta, the managing director of Lupin said the company is  delighted with the receipt of the EIR for Aurangabad classifying the inspection as No Action Indicated.

Pharma major Lupins Aurangabad facility gets Establishment Inspection Report from USFDA

Representative image. Image source: Pixabay

"This takes us a step forward in our efforts of enhancing our compliance and quality standards across all our manufacturing sites. We continue to work with the USFDA to continuously improve our quality and compliance while providing important medicines to the US market,” Gupta added.

The report added that Lupin saw a net loss of Rs 835 crore in December 2019 against a net loss of Rs 151.75 crore in Q3 December 2018.

Lupin Pharmaceuticals are known to make branded and generic medications that are used across the world.

The company has a state-of-the-art R&D center in Pune and creates Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents). It also has a  presence in the areas of diabetes, anti-inflammatory and respiratory therapy.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection
science

Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection

The Covihalt tablet will be available in 200 mg tablets in a strip of 10 and will cost Rs 49 per tablet in India.

'Nobody likes me': Donald Trump complains approval rating is lower than Anthony Fauci's
World

'Nobody likes me': Donald Trump complains approval rating is lower than Anthony Fauci's

When Donald Trump restarted his coronavirus briefings last week after shutting them down in April, he largely hewed to a script, urging Americans to wear masks and practice social distancing

Drugs body CDSCO suspends import licences of 19 firms for non-USFDA COVID-19 testing kits
India

Drugs body CDSCO suspends import licences of 19 firms for non-USFDA COVID-19 testing kits

The decision was taken after the drug controller found the companies' response to a 17 July show-cause notice asking them to explain why their licences should not be suspended unsatisfactory